RxDoctor Payments Data

David Jackson, MD

Cardiovascular Disease · Columbia, MDNPI 1891796900

Payments from drug & device makers

$25,687in general payments, 2019–2025

Across 85 payments — averaging $302.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Esperion Therapeutics, Inc.$13K
  • Pfizer$8K
  • E.r. Squibb & Sons, L.L.C.$3K
  • Abbott$390
  • Johnson & Johnson$227
  • Akcea Therapeutics, Inc.$217
  • plus $904 from 16 others

What the payments were for

  • Speaking & faculty fees$22,97089%
  • Food & beverage$2,68910%
  • Education$280%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,687 in reported general payments places this provider in the 85th percentile of 507 cardiovascular disease providers in Maryland.

See all cardiovascular disease providers in Maryland

Medicare billing

Part B allowed, 2024
$367,538
Medicare patients
1,133
Services billed
5,782

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban401$530,827
EntrestoSacubitril/Valsartan67$127,441
Repatha SureclickEvolocumab81$114,801
XareltoRivaroxaban54$82,753
Praluent PenAlirocumab62$50,621
JardianceEmpagliflozin28$35,046
MultaqDronedarone Hcl12$27,021
NexletolBempedoic Acid22$24,908
BrilintaTicagrelor18$20,470
MounjaroTirzepatide13$16,659
LivaloPitavastatin Calcium14$12,376
Ezetimibe278$11,485
Metoprolol Succinate578$9,681
Irbesartan326$6,990
Atorvastatin Calcium518$6,735

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$8,222$530,827401 claims
NovartisEntresto$161$127,44167 claims
Johnson & JohnsonXarelto$227$82,75354 claims
Boehringer IngelheimJardiance$17$35,04628 claims
Sanofi-aventis U.S. LLCMultaq$17$27,02112 claims
Esperion Therapeutics, Inc.Nexletol$12,817$24,90822 claims
Lilly USA, LLCMounjaro$36$16,65913 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 cardiovascular disease providers in Maryland.

Other cardiovascular disease in Columbia

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →